July 30, 2015
Quarterly Cash Flow & Activities Report – GSS Appendix 4C 30 June 2015
August 13, 2015
Genetic Signatures expands into multiple European countries for its infectious disease detection products
- Further expansion for EasyScreen™ Pathogen Detection products
- Distribution deals signed for Ireland and Poland
- Agreements support Genetic Signatures’ strategy of global market penetration and increased market share
Molecular diagnostics company Genetic Signatures (ASX: GSS) has announced that it has signed distribution deals for Ireland and Poland, further expanding the market reach for its EasyScreen™ Products.
August 27, 2015
GSS Amended Appendix 4E and Audited Financial Report 30 June 2015
September 15, 2015
Appointment to Board of Directors – Dr Tony Radford
Genetic Signatures Limited (ASX: GSS) is pleased to announce the appointment of Dr Tony Radford to the Board of Directors of the Company.
Tony Radford has a PhD from La Trobe University, and was a member of the CSIRO team that invented the QuantiFERON method for Cellular Immune based diagnostics. He later joined AMRAD in pharmaceutical research and was Head of Development in 2000 when he left to co-found the diagnostic company Cellestis Limited, which listed on the ASX in 2001. Establishing offices and operations in the USA, Europe and Japan, Cellestis developed QuantiFERON –TB Gold, the worldwide benchmark for diagnosis of tuberculosis infection. Dr Radford was CEO of Cellestis from founding until its acquisition by QIAGEN NV in 2011 for approximately $400 million.
September 12, 2016
Notice of Extraordinary General Meeting/Proxy Form
Notice is given that the Extraordinary General Meeting of members of Genetic Signatures Limited (Company or Genetic Signatures) will be held as follows:
Date: Thursday, 13 October 2016
Time: 11.00am (AEDT)
Venue: BDO Level 11 1 Margaret Street Sydney NSW 2000
September 2, 2016
Genetic Signatures Limited Completes $14m Capital Raising
Molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) is pleased to announce that it has successfully completed an institutional placement to raise $14 million through the issue of 29.8 million new shares (Offer).
The proceeds from the Offer will be used for commercial expansion in Australia, the European Union and USA, obtaining further regulatory approvals for Genetic Signatures’ products, continued product development and working capital purposes.
August 30, 2016
Preliminary Final Report – GSS Appendix 4E 30 June 2016
July 22, 2016
GSS Non-Deal Roadshow Presentation – July 2016
July 21, 2016
Quarterly Cash Flow & Activities Report – GSS Appendix 4C 30 June 2016
June 17, 2016
Genetic Signatures Launches Analyte Specific Reagents in the US
- Further step towards full product suite commercialisation in the US
- Allows uptake of Genetic Signatures 3base™ technology in up to 11,000 CLIA certified laboratories in the US
- To be officially launched during the American Society of Microbiology conference on June 17, 2016
Sydney, Australia, 17 June, 2016: Molecular diagnostics company Genetic Signatures Ltd (ASX: GSS) will today launch a range of Analyte Specific Reagents (ASRs) in the United States. These ASR products utilise the company’s proprietary 3base™ technology and cover a range of pathogen targets. US Laboratories regulated by the Clinical Laboratory Improvement Act (CLIA) may purchase and use ASRs as building blocks to develop and validate proprietary tests for the diagnosis of infectious diseases. These laboratory-developed tests are commonly used in the US market and are offered in up to 11,000 CLIA certified laboratories1.
The ASR products will be officially launched at the American Society of Microbiology conference, Boston, June 17-20, 2016. Genetic Signatures will be exhibiting and showcasing their full product range to more than 10,000 attendees.
“We know that the market in the US seeks technologically superior products that may be used in laboratory-developed tests.” said Mr. Mike Aicher, President of Genetic Signatures US. “This is the next logical step for Genetic Signatures after FDA listing of our Clinical Concentrator Kit, which we completed in August of 2015.”
“This progressive step in our US market entry strategy brings our proprietary 3Base™ technology to the majority of hospital and commercial laboratories in the US,” said Genetic Signatures’ Chief Executive Officer, John Melki PhD. “We believe that our technologically superior ASRs will be well received by the American market.”
About Analyte Specific Reagents: The US Food and Drug Administration (FDA) defines Analyte Specific Reagents as “antibodies, both polyclonal and monoclonal, specific receptor proteins, ligands, nucleic acid sequences, and similar reagents, which through specific binding or chemical reactions with substances in a specimen, are intended for use in a diagnostic application for identification and quantification of an individual chemical substance or ligand in biological specimens.” 21 CFR 864.4020